Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGC Flora Growth	$23.50 +17.6%	$24.39	$15.15 ▼ $82.29	$11.54M	1.97	14,772 shs	29,551 shs
GOVX GeoVax Labs	$0.75 +1.6%	$0.80	$0.43 ▼ $11.18	$11.77M	3.27	1.24 million shs	432,112 shs
PCSA Heatwurx	$0.22 -3.4%	$0.24	$0.15 ▼ $1.58	$2.71M	1.32	6.09 million shs	2.39 million shs
PHIO Phio Pharmaceuticals	$2.19	$2.40	$0.97 ▼ $9.79	$10.51M	0.86	2.68 million shs	137,596 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGC Flora Growth	+13.86%	+34.90%	-10.07%	-10.84%	-33.78%
GOVX GeoVax Labs	+1.49%	+12.19%	+8.82%	-23.74%	-76.89%
PCSA Heatwurx	-3.42%	-4.72%	+7.21%	-6.18%	-83.69%
PHIO Phio Pharmaceuticals	0.00%	-2.67%	-7.98%	+19.02%	-15.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FLGC Flora Growth	3.1868 of 5 stars	3.3	5.0	3.4	0.8	0.6
GOVX GeoVax Labs	1.681 of 5 stars	3.5	2.0	1.3	0.0	0.6
PCSA Heatwurx	3.0055 of 5 stars	3.5	4.0	1.1	1.7	1.3
PHIO Phio Pharmaceuticals	2.8428 of 5 stars	3.5	2.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLGC Flora Growth	3.00	Buy	$93.00	295.74% Upside
GOVX GeoVax Labs	3.00	Buy	$8.88	1,081.76% Upside
PCSA Heatwurx	3.00	Buy	$2.00	808.27% Upside
PHIO Phio Pharmaceuticals	3.00	Buy	$14.00	539.27% Upside

Current Analyst Ratings Breakdown

Latest PCSA, FLGC, GOVX, and PHIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
8/5/2025	FLGC Flora Growth	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00
7/29/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/17/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00
6/25/2025	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLGC Flora Growth	$59.51M	0.23	N/A	N/A	$6.96 per share	3.38
GOVX GeoVax Labs	$3.95M	3.03	N/A	N/A	$0.18 per share	4.17
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.51 per share	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$0.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLGC Flora Growth	-$15.91M	-$34.38	N/A	N/A	N/A	-24.86%	-261.57%	-48.06%	N/A
GOVX GeoVax Labs	-$24.99M	-$2.01	N/A	N/A	N/A	-403.88%	-408.80%	-279.89%	N/A
PCSA Heatwurx	-$11.85M	-$2.32	N/A	N/A	N/A	N/A	-342.36%	-243.48%	10/29/2025 (Estimated)
PHIO Phio Pharmaceuticals	-$7.15M	-$6.42	N/A	0.58	N/A	N/A	-105.65%	-89.19%	N/A

Latest PCSA, FLGC, GOVX, and PHIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PHIO Phio Pharmaceuticals	-$0.36	-$0.45	-$0.09	-$0.45	N/A	N/A
8/7/2025	Q2 2025	PCSA Heatwurx	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A
8/1/2025	Q2 2025	FLGC Flora Growth	-$0.06	-$0.11	-$0.05	-$0.11	$11.77 million	$14.80 million
7/28/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	-$0.35	+$0.06	-$0.35	$0.37 million	$0.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLGC Flora Growth	0.50	0.96	0.61
GOVX GeoVax Labs	N/A	2.03	2.03
PCSA Heatwurx	N/A	3.45	3.45
PHIO Phio Pharmaceuticals	N/A	10.58	10.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLGC Flora Growth	36.01%
GOVX GeoVax Labs	6.09%
PCSA Heatwurx	91.93%
PHIO Phio Pharmaceuticals	57.31%

Insider Ownership

Company	Insider Ownership
FLGC Flora Growth	12.56%
GOVX GeoVax Labs	1.20%
PCSA Heatwurx	9.60%
PHIO Phio Pharmaceuticals	0.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLGC Flora Growth	280	580,000	505,000	Not Optionable
GOVX GeoVax Labs	10	15.93 million	15.73 million	Not Optionable
PCSA Heatwurx	20	11.88 million	10.74 million	Not Optionable
PHIO Phio Pharmaceuticals	10	4.80 million	4.76 million	Not Optionable

PCSA, FLGC, GOVX, and PHIO Headlines

Recent News About These Companies

Phio Posts Wider Loss in Fiscal Q2

4 hours ago | aol.comA

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 4:19 PM | newsfilecorp.comN

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 4:15 PM | newsfilecorp.comN

Phio Pharmaceuticals (PHIO) Expected to Announce Earnings on Wednesday

August 11, 2025 | americanbankingnews.com

Phio Pharmaceuticals stock soars after manufacturing agreement

July 25, 2025 | za.investing.com

Phio Pharmaceuticals Shares Rise After New Development Services Agreement

July 25, 2025 | marketwatch.com

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

July 25, 2025 | newsfilecorp.comN

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

July 25, 2025 | newsfilecorp.comN

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

July 25, 2025 | newsfilecorp.comN

Phio Pharmaceuticals Corp. (PHIO) Latest Press Releases & Corporate ...

July 16, 2025 | finance.yahoo.com

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer ... - FinanzNachrichten.de

June 27, 2025 | finanznachrichten.de

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

June 25, 2025 | newsfilecorp.comN

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

June 24, 2025 | newsfilecorp.comN

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

June 6, 2025 | newsfilecorp.comN

Best Value Stocks to Buy for May 28th

May 28, 2025 | zacks.com

New Strong Buy Stocks for May 28th

May 28, 2025 | zacks.com

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025 | newsfilecorp.comN

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | newsfilecorp.comN

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025 | finanznachrichten.de

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA, FLGC, GOVX, and PHIO Company Descriptions

Flora Growth NASDAQ:FLGC

$23.50 +3.52 (+17.62%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$23.50 0.00 (-0.02%)

As of 08/14/2025 07:59 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

GeoVax Labs NASDAQ:GOVX

$0.75 +0.01 (+1.62%)

As of 08/14/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Heatwurx NASDAQ:PCSA

$0.22 -0.01 (-3.42%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.22 +0.00 (+2.18%)

As of 04:03 AM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Phio Pharmaceuticals NASDAQ:PHIO

$2.19 0.00 (0.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.16 -0.02 (-1.14%)

As of 08/14/2025 07:50 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time